Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Surgical outcomes of excisional goniotomy using the kahook dual blade in severe and refractory glaucoma: 12-month results

Abstract

Objectives

To describe the efficacy and safety of goniotomy with trabecular meshwork excision using the Kahook Dual Blade (KDB, New World Medical Inc., Rancho Cucamonga, CA) in patients with severe or refractory glaucoma.

Methods

This retrospective multicentre case series reports on 40 eyes with severe or refractory open-angle glaucoma that underwent standalone or combined KDB goniotomy and were followed for 12 months post-operatively in the United-States, Mexico and Switzerland. Surgical success was defined as an intraocular pressure (IOP) reduction ≥20% from baseline at 12 months, with fewer medications than preoperatively. Mean IOP and antiglaucoma medication reduction, probabilities of achieving an IOP ≤16 or 18 mmHg, and adverse events were also analysed.

Results

Mean IOP decreased from 18.1 ± 5.0 mmHg at baseline to 14.8 ± 3.7 mmHg at 12 months (18.2% reduction, P < 0.001). Concomitantly, the mean number of glaucoma medications decreased from 2.5 ± 1.4 to 1.7 ± 1.2 (32% reduction, P = 0.002). The proportion of eyes achieving an IOP reduction of more than 20% from baseline was 37.5% (n = 15) at 12 months. At 12 months, 67.5% and 82.5% achieved a medicated IOP ≤ 16 and ≤18 mmHg, respectively. No severe complications were reported.

Conclusion

Excisional goniotomy with KDB achieves a statistically significant IOP and antiglaucoma medication reduction in severe or refractory glaucoma over a period of 12 months. While its efficacy decreases with time, its favourable safety profile makes it a potentially useful primary or adjunctive procedure in high-risk eyes.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Mean intraocular pressure.
Fig. 2: Number of antiglaucoma medications.
Fig. 3: Cumulative probability of success rate.

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. Jama. 2014;311:1901–11.

    Article  Google Scholar 

  2. Mansouri K, Medeiros FA, Weinreb RN. Global rates of glaucoma surgery. Graefes Arch Clin Exp Ophthalmol. 2013;251:2609–15.

    Article  Google Scholar 

  3. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153:804–14.e1.

    Article  Google Scholar 

  4. Arora KS, Robin AL, Corcoran KJ, Corcoran SL, Ramulu PY. Use of various glaucoma surgeries and procedures in medicare beneficiaries from 1994 to 2012. Ophthalmology. 2015;122:1615–24.

    Article  Google Scholar 

  5. Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PloS One. 2017;12:e0183142.

    Article  Google Scholar 

  6. Gillmann K, Mansouri K. Minimally invasive glaucoma surgery: where is the evidence? Asia Pac J Ophthalmol (Philos). 2020;9:203–14.

    Article  Google Scholar 

  7. Gillmann K, Mansouri K, Ambresin A, Bravetti GE, Mermoud A. A prospective analysis of istent inject microstent implantation: surgical outcomes, endothelial cell density, and device position at 12 months. J Glaucoma. 2020;29:639–47.

    Article  Google Scholar 

  8. Wellik SR, Dale EA. A review of the iStent(®) trabecular micro-bypass stent: safety and efficacy. Clin Ophthalmol. 2015;9:677–84.

    Article  Google Scholar 

  9. Chaudhary A, Salinas L, Guidotti J, Mermoud A, Mansouri K. XEN Gel Implant: a new surgical approach in glaucoma. Expert Rev Med devices. 2018;15:47–59.

    CAS  Article  Google Scholar 

  10. Schlenker MB, Gulamhusein H, Conrad-Hengerer I, Somers A, Lenzhofer M, Stalmans I, et al. Efficacy, safety, and risk factors for failure of standalone Ab interno gelatin microstent implantation versus standalone trabeculectomy. Ophthalmology. 2017;124:1579–88.

    Article  Google Scholar 

  11. Mansouri K, Guidotti J, Rao HL, Ouabas A, D’Alessandro E, Roy S, et al. Prospective evaluation of standalone XEN gel implant and combined phacoemulsification-XEN gel implant surgery: 1-year results. J Glaucoma. 2018;27:140–7.

    Article  Google Scholar 

  12. Mansouri K, Bravetti GE, Gillmann K, Rao HL, Ch’ng TW, Mermoud A. Two-year outcomes of XEN gel stent surgery in patients with open-angle glaucoma. Ophthalmol Glacoma. 2019;2:309–18.

  13. Gillmann K, Bravetti GE, Rao HL, Mermoud A, Mansouri K. Combined and stand-alone XEN 45 gel stent implantation: 3-year outcomes and success predictors. Acta Ophthalmologica. 2020;99:e531–9.

  14. Gillmann K, Bravetti GE, Rao HL, Mermoud A, Mansouri K. Impact of phacoemulsification combined with XEN gel stent implantation on corneal endothelial cell density: 2-year results. J Glaucoma. 2020;29:155–60.

    Article  Google Scholar 

  15. Mansouri K, Gillmann K, Rao HL, Guidotti J, Mermoud A. Prospective evaluation of XEN gel implant in eyes with pseudoexfoliative glaucoma. J Glaucoma. 2018;27:869–73.

    Article  Google Scholar 

  16. Gillmann K, Bravetti GE, Mermoud A, Rao HL, Mansouri K. XEN gel stent in pseudoexfoliative glaucoma: 2-year results of a prospective evaluation. J Glaucoma. 2019;28:676–84.

    Article  Google Scholar 

  17. Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res. 2009;88:648–55.

    CAS  Article  Google Scholar 

  18. Grant WM. Clinical measurements of aqueous outflow. Am J Ophthalmol. 1951;34:1603–5.

    CAS  Article  Google Scholar 

  19. SooHoo JR, Seibold LK, Kahook MY. Ab interno trabeculectomy in the adult patient. Middle East Afr J Ophthalmol. 2015;22:25–9.

    Article  Google Scholar 

  20. Seibold LK, Soohoo JR, Ammar DA, Kahook MY. Preclinical investigation of ab interno trabeculectomy using a novel dual-blade device. Am J Ophthalmol. 2013;155:524–9.e2.

    Article  Google Scholar 

  21. Parekh AS, Tafreshi A, Dorairaj SK, Weinreb RN. Clinical applicability of the International Classification of Disease and Related Health Problems (ICD-9) glaucoma staging codes to predict disease severity in patients with open-angle glaucoma. J Glaucoma. 2014;23:e18–22.

    Article  Google Scholar 

  22. Greenwood MD, Seibold LK, Radcliffe NM, Dorairaj SK, Aref AA, Román JJ, et al. Goniotomy with a single-use dual blade: Short-term results. J Cataract Refract Surg. 2017;43:1197–201.

    Article  Google Scholar 

  23. Dixon MW, Moulin TA, Margolis MS, Palko JR, Mortensen P, Conner IP, et al. Comparative outcomes of the molteno3 and baerveldt glaucoma implants. Ophthalmol Glaucoma. 2020;3:40–50.

    Article  Google Scholar 

  24. Bravetti GE, Mansouri K, Gillmann K, Rao HL, Mermoud A. XEN-augmented Baerveldt drainage device implantation in refractory glaucoma: 1-year outcomes. Graefes Arch Clin Exp Ophthalmol. 2020;258:1787–94.

  25. Arad T, Hoffmann EM, Prokosch-Willing V, Pfeiffer N, Grehn F. XEN-augmented baerveldt implantation for refractory childhood glaucoma: a retrospective case series. J Glaucoma. 2019;28:1015–8.

    Article  Google Scholar 

  26. Salinas L, Chaudhary A, Berdahl JP, Lazcano-Gomez GS, Williamson BK, Dorairaj SK, et al. Goniotomy using the kahook dual blade in severe and refractory glaucoma: 6-month outcomes. J Glaucoma. 2018;27:849–55.

    Article  Google Scholar 

  27. Miller VJ, Young CEC, SooHoo JR, Seibold LK, Kahook MY, Pecen PE, et al. Efficacy of goniotomy with kahook dual blade in patients with uveitis-associated ocular hypertension. J Glaucoma. 2019;28:744–8.

    Article  Google Scholar 

  28. ElMallah MK, Seibold LK, Kahook MY, Williamson BK, Singh IP, Dorairaj SK. 12-month retrospective comparison of kahook dual blade excisional goniotomy with istent trabecular bypass device implantation in glaucomatous eyes at the time of cataract surgery. Adv Ther. 2019;36:2515–27.

    Article  Google Scholar 

  29. Wakil SM, Birnbaum F, Vu DM, McBurney-Lin S, ElMallah MK, Tseng H. Efficacy and safety of kahook dual blade goniotomy: 18-month results. J Cataract Refract Surg. 2020.

  30. ElMallah MK, Berdahl JP, Williamson BK, Dorairaj SK, Kahook MY, Gallardo MJ, et al. Twelve-month outcomes of stand-alone excisional goniotomy in mild to severe glaucoma. Clin Ophthalmol. 2020;14:1891–7.

    Article  Google Scholar 

  31. Sleath B, Blalock SJ, Carpenter DM, Sayner R, Muir KW, Slota C, et al. Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence. Ophthalmology. 2015;122:748–54.

    Article  Google Scholar 

  32. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–23.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

Supported in part by the Swiss Glaucoma Research Foundation, Lausanne, Switzerland.

Author information

Authors and Affiliations

Authors

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by, Kaweh Mansouri, Kevin Gillmann and Giorgio Enrico Bravetti. The first draft of the manuscript was written by Giorgio Enrico Bravetti. Kaweh Mansouri and Kevin Gillmann commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Giorgio Enrico Bravetti.

Ethics declarations

Competing interests

JPB: Alcon, Allergan, Bausch and Lomb, CorneaGen, Dakota Lions Eye Bank, Equinox, Expert Opinion, Glaucos, Gore, Imprimis/Harrow Health, JNJ, Kala, Kedalion, MELT Pharmaceuticals, MicroOptix, New World Medical, Ocular Surgical Data, Ocular Theraputix, Omega Ophthalmic, Orasis, Oyster Point, RxSight, Surface Inc., Tarsus, Tear Clear, Vittamed, Vance Thompson Vision, Verana Health (Digisight), Visionary Ventures, Zeiss. Lazcano-Gomez GSL-G: New World Medical. BKW: New World Medical. SKD: New World Medical, Iridex. LS: New World Medical. AAA: New World Medical, Aerie Pharmaceuticals, Bausch and Lomb. AM: Allergan, Bausch and Lomb, Iridex, New World Medical. KM: Santen, Sensimed, Topcon, Alcon, Allergan, Optovue, ImplantData. Others: no financial disclosures.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bravetti, G.E., Gillmann, K., Salinas, L. et al. Surgical outcomes of excisional goniotomy using the kahook dual blade in severe and refractory glaucoma: 12-month results. Eye (2022). https://doi.org/10.1038/s41433-022-02196-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41433-022-02196-y

Search

Quick links